Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist

European Journal of Pharmacology

Volumn 369, Issue 3, 1999, Pages 313-317

  Von Lubitz, Dag K J E ^a   Lin, Rick C S ^b   Bischofberger, Norbert ^c   Beenhakker, Mark ^d   Boyd, Mellonie ^d   Lipartowska, Renata ^e   Jacobson, Kenneth A ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c GILEAD SCIENCES   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e Department of Pharmacology School of Medicine ^*  (Poland)

Author keywords

Adenosine A1 receptor; Cerebral ischemia; Gerbil; Therapy

Indexed keywords

ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE AMINE CONGENER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; FEMALE; GERBIL; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; LONG TERM CARE; MORTALITY; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

EID: 0032892059     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00073-4     Document Type: Article

References (26)

1. 1 receptor agonists as clinically viable agents in treatment of ischemic brain disorders. In: Trembly, B., Slikker, W., Jr. (Eds.), Neuroprotective Agents: Third International Conference, Ann. New York Acad. Sci., Vol. 825, New York, pp. 23-29.
2. 3 receptor agonists on astrocytes: induction of cell protection at low and cell death at high concentrations. Drug Dev. Res. 3:1996;177.
3. Daly, J.W., Jacobson, K.A., 1995. Adenosine receptors: selective agonists and antagonists. In: Belardinelli, L., Pelleg, A. (Eds.), Adenine and Adenosine Nucleotides: From Molecular Biology to Integrative Physiology. Kluwer Academic Publishers, Norwell, pp. 157-166.
4. 1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene. Eur. J. Pharmacol. 317:1996;239-245.
5. 1 receptor number. Brain Res. 612:1993;271-277.
6. 1 adenosine receptors. In: Belardinelli, L., Pelleg, A. (Eds.), Adenine and Adenosine Nucleotides: From Molecular Biology to Integrative Physiology. Kluwer Academic Publishers, Norwel, pp. 133-138.
7. Jacobson K.A., Kirk K.L., Padgett W.L., Daly J.W. Probing adenosine receptors with adenosine and xanthine biotin conjugates. FEBS Lett. 184:1985;30-35.
8. Jacobson K.A., Von Lubitz D.K.J.E., Daly J.W., Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17:1996;108-138.
9. Knutsen, L.J.S., Lau, J., Sheardown, M.J., Eskesen, K., Thomsen, C., Weis, J.U., Judge, M.E., Klitgaard, H., 1995. Anticonvulsant actions of novel and reference adenosine agonists. In: Belardinelli, L., Pelleg, A. (Eds.), Adenine and Adenosine Nucleotides: From Molecular Biology to Integrative Physiology. Kluwer Academic Publishers, Norwell, pp. 479-487.
10. 1 receptor-mediated inhibition of cardiac myocyte contractility and adenylate cyclase activity. Relation to the regulation of receptor affinity and density. Circ. Res. 67:1990;406-414.
11. iα are not associated with changes in their mRNAs. Mol. Pharmacol. 36:1989;681-688.
12. Loskota, W.J., Lomax, P., Verity, M.A., 1974. A Stereotaxic Atlas of the Mongolian Gerbil Brain. Ann Arbor Sci. Publ., Ann Arbor, MI, pp. 1-157.
13. 1 selective agonists. J. Pharm. Sci. 1:1993;46-53.
14. 3 adenosine receptor. J. Biol. Chem. 28:1995;16895-16902.
15. 1 adenosine receptor adenylate cyclase system in rat adipocytes. J. Biol. Chem. 262:1987;841-847.
16. Rudolphi, K., Schubert, P., 1996. Purinergic interventions in traumatic and ischemic injury. In: Peterson, P.L., Phillis, J.W. (Eds.), Novel Therapies for CNS Injuries: Rationales and Results. CRC Press, Boca Raton, FL, pp. 327-337.
17. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Adenosine and brain ischemia. Cerebrovasc. Brain Metab. Rev. 4:1992;346-369.
18. Sheardown, M.J., Hansen, A.J., Thomsen, C., Judge, M.E., Knutsen, L.J.S., 1995. Novel adenosine agonists: a strategy for stroke therapy. In: Grotta, J., Miller, L.P., Buchan, A.M. (Eds.), Ischemic Stroke: Recent Advances in Understanding and Therapy. International Business Communications, Scarborough, MA, pp. 187-214.
19. Von Lubitz, D.K.J.E., Jacobson, K.A., 1995. Behavioral effects of adenosine receptor stimulation. In: Belardinelli, L., Pelleg, A. (Eds.), Adenosine and Adenine Nucleotides: From Molecular to Integrative Physiology. Kluwer Academic Publishers, Norwell, pp. 489-498.
20. 1 receptor agonist or antagonist in cerebral ischemia. Eur. J. Pharmacol. 256:1994;161-167.
21. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 263:1994;59-67.
22. Von Lubitz, D.K.J.E., Carter, M.F., Beenhakker, M., Lin, R.C.-S., Jacobson, K.A., 1995a, Adenosine: a prototherapeutic concept in neurodegeneration. In: Trembly, B., Slikker, W., Jr. (Eds.), Neuroprotective Agents. Proceedings of II International Conference, Ann. New York Acad. Sci., Vol. 765, New York, pp. 163-178.
23. 2A agonist and antagonist. Eur. J. Pharmacol. 287:1995;295-302.
24. 1 receptor agonist. Eur. J. Pharmacol. 302:1996;43-48.
25. Von Lubitz D.K.J.E., Lin R.C.-S., Paul I.A., Beenhakker M., Boyd M., Bischofberger N., Jacobson K.A. Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils. Eur. J. Pharmacol. 316:1996;171-179.
26. Williams M. Purinergic drugs: opportunities in the 1990s. Drug Dev. Res. 28:1993;438-441.